PARP1 and ovarian cancer: Based on these results, we conclude that sensitivity to PARP inhibitory drug treatment did not discriminate between case and control groups, whereas increased carboplatin sensitivity was associated with hereditary breast and ovarian cancer risk as well as early-onset ovarian cancer.